Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

Inclusion Criteria:

• Patients eligible to start a treatment including immune checkpoint inhibitors (Nivolumab, Ipilimumab, Pembrolizumab, and so on…)

• Diagnosis of advanced or metastatic melanoma or NSCLC (All treatment lines will beallowed)

• Age ≥ 70 years

• Having personally signed and dated informed consent

• Patient affiliated to the ''National security'' regimen or beneficiary of thisregimen

Exclusion Criteria:

• Immune checkpoint inhibitor therapy initiated before study enrolment

• Concomitant participation in other investigational clinical trials involving animmune checkpoint inhibitor

• Immune checkpoint inhibitor treatment in a context of other solid tumours

• Immune checkpoint inhibitor treatment in a context of haematological malignancies

• Being unable or unwilling to comply with the requirements of the protocol, asassessed by the investigator

• Patient in urgency situation, adult under legal protection, or unable to give hisconsent